Cargando…

Percutaneous Left Atrial Appendage Occlusion: An Emerging Option in Patients with Atrial Fibrillation at High Risk of Bleeding

Atrial fibrillation (AF) is a common cardiac arrhythmia with an estimated prevalence of 1% in the general population. It is associated with an increased risk of ischemic stroke, silent cerebral ischemia, and cognitive impairment. Due to the blood flow stasis and morphology, thrombus formation occurs...

Descripción completa

Detalles Bibliográficos
Autores principales: Cimmino, Giovanni, Loffredo, Francesco S., Gallinoro, Emanuele, Prozzo, Dario, Fabiani, Dario, Cante, Luigi, Salerno, Gemma, Cappelli Bigazzi, Maurizio, Golino, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8147783/
https://www.ncbi.nlm.nih.gov/pubmed/34063719
http://dx.doi.org/10.3390/medicina57050444
_version_ 1783697703377567744
author Cimmino, Giovanni
Loffredo, Francesco S.
Gallinoro, Emanuele
Prozzo, Dario
Fabiani, Dario
Cante, Luigi
Salerno, Gemma
Cappelli Bigazzi, Maurizio
Golino, Paolo
author_facet Cimmino, Giovanni
Loffredo, Francesco S.
Gallinoro, Emanuele
Prozzo, Dario
Fabiani, Dario
Cante, Luigi
Salerno, Gemma
Cappelli Bigazzi, Maurizio
Golino, Paolo
author_sort Cimmino, Giovanni
collection PubMed
description Atrial fibrillation (AF) is a common cardiac arrhythmia with an estimated prevalence of 1% in the general population. It is associated with an increased risk of ischemic stroke, silent cerebral ischemia, and cognitive impairment. Due to the blood flow stasis and morphology, thrombus formation occurs mainly in the left atrial appendage (LAA), particularly in the setting of nonvalvular AF (NVAF). Previous studies have shown that >90% of emboli related to NVAF originate from the LAA, thus prevention of systemic cardioembolism is indicated. According to the current guidelines, anticoagulant therapy with direct oral anticoagulants (DOACs) or vitamin K antagonists (VKAs), represents the standard of care in AF patients, in order to prevent ischemic stroke and peripheral embolization. Although these drugs are widely used and DOACs have shown, compared to VKAs, non-inferiority for stroke prevention with significantly fewer bleeding complications, some issues remain a matter of debate, including contraindications, side effects, and adherence. An increasing number of patients, indeed, because of high bleeding risk or after experiencing life-threatening bleedings, must take anticoagulants with extreme caution if not contraindicated. While surgical closure or exclusion of LAA has been historically used in patients with AF with contradictory results, in the recent years, a novel procedure has emerged to prevent the cardioembolic stroke in these patients: The percutaneous left atrial appendage occlusion (LAAO). Different devices have been developed in recent years, though not all of them are approved in Europe and some are still under clinical investigation. Currently available devices have shown a significant decrease in bleeding risk while maintaining efficacy in preventing thromboembolism. The procedure can be performed percutaneously through the femoral vein access, under general anesthesia. A transseptal puncture is required to access left atrium and is guided by transesophageal echocardiography (TEE). Evidence from the current literature indicates that percutaneous LAAO represents a safe alternative for those patients with contraindications for long-term oral anticoagulation. This review summarizes scientific evidences regarding LAAO for stroke prevention including clinical indications and an adequate patient selection.
format Online
Article
Text
id pubmed-8147783
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81477832021-05-26 Percutaneous Left Atrial Appendage Occlusion: An Emerging Option in Patients with Atrial Fibrillation at High Risk of Bleeding Cimmino, Giovanni Loffredo, Francesco S. Gallinoro, Emanuele Prozzo, Dario Fabiani, Dario Cante, Luigi Salerno, Gemma Cappelli Bigazzi, Maurizio Golino, Paolo Medicina (Kaunas) Review Atrial fibrillation (AF) is a common cardiac arrhythmia with an estimated prevalence of 1% in the general population. It is associated with an increased risk of ischemic stroke, silent cerebral ischemia, and cognitive impairment. Due to the blood flow stasis and morphology, thrombus formation occurs mainly in the left atrial appendage (LAA), particularly in the setting of nonvalvular AF (NVAF). Previous studies have shown that >90% of emboli related to NVAF originate from the LAA, thus prevention of systemic cardioembolism is indicated. According to the current guidelines, anticoagulant therapy with direct oral anticoagulants (DOACs) or vitamin K antagonists (VKAs), represents the standard of care in AF patients, in order to prevent ischemic stroke and peripheral embolization. Although these drugs are widely used and DOACs have shown, compared to VKAs, non-inferiority for stroke prevention with significantly fewer bleeding complications, some issues remain a matter of debate, including contraindications, side effects, and adherence. An increasing number of patients, indeed, because of high bleeding risk or after experiencing life-threatening bleedings, must take anticoagulants with extreme caution if not contraindicated. While surgical closure or exclusion of LAA has been historically used in patients with AF with contradictory results, in the recent years, a novel procedure has emerged to prevent the cardioembolic stroke in these patients: The percutaneous left atrial appendage occlusion (LAAO). Different devices have been developed in recent years, though not all of them are approved in Europe and some are still under clinical investigation. Currently available devices have shown a significant decrease in bleeding risk while maintaining efficacy in preventing thromboembolism. The procedure can be performed percutaneously through the femoral vein access, under general anesthesia. A transseptal puncture is required to access left atrium and is guided by transesophageal echocardiography (TEE). Evidence from the current literature indicates that percutaneous LAAO represents a safe alternative for those patients with contraindications for long-term oral anticoagulation. This review summarizes scientific evidences regarding LAAO for stroke prevention including clinical indications and an adequate patient selection. MDPI 2021-05-03 /pmc/articles/PMC8147783/ /pubmed/34063719 http://dx.doi.org/10.3390/medicina57050444 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Cimmino, Giovanni
Loffredo, Francesco S.
Gallinoro, Emanuele
Prozzo, Dario
Fabiani, Dario
Cante, Luigi
Salerno, Gemma
Cappelli Bigazzi, Maurizio
Golino, Paolo
Percutaneous Left Atrial Appendage Occlusion: An Emerging Option in Patients with Atrial Fibrillation at High Risk of Bleeding
title Percutaneous Left Atrial Appendage Occlusion: An Emerging Option in Patients with Atrial Fibrillation at High Risk of Bleeding
title_full Percutaneous Left Atrial Appendage Occlusion: An Emerging Option in Patients with Atrial Fibrillation at High Risk of Bleeding
title_fullStr Percutaneous Left Atrial Appendage Occlusion: An Emerging Option in Patients with Atrial Fibrillation at High Risk of Bleeding
title_full_unstemmed Percutaneous Left Atrial Appendage Occlusion: An Emerging Option in Patients with Atrial Fibrillation at High Risk of Bleeding
title_short Percutaneous Left Atrial Appendage Occlusion: An Emerging Option in Patients with Atrial Fibrillation at High Risk of Bleeding
title_sort percutaneous left atrial appendage occlusion: an emerging option in patients with atrial fibrillation at high risk of bleeding
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8147783/
https://www.ncbi.nlm.nih.gov/pubmed/34063719
http://dx.doi.org/10.3390/medicina57050444
work_keys_str_mv AT cimminogiovanni percutaneousleftatrialappendageocclusionanemergingoptioninpatientswithatrialfibrillationathighriskofbleeding
AT loffredofrancescos percutaneousleftatrialappendageocclusionanemergingoptioninpatientswithatrialfibrillationathighriskofbleeding
AT gallinoroemanuele percutaneousleftatrialappendageocclusionanemergingoptioninpatientswithatrialfibrillationathighriskofbleeding
AT prozzodario percutaneousleftatrialappendageocclusionanemergingoptioninpatientswithatrialfibrillationathighriskofbleeding
AT fabianidario percutaneousleftatrialappendageocclusionanemergingoptioninpatientswithatrialfibrillationathighriskofbleeding
AT canteluigi percutaneousleftatrialappendageocclusionanemergingoptioninpatientswithatrialfibrillationathighriskofbleeding
AT salernogemma percutaneousleftatrialappendageocclusionanemergingoptioninpatientswithatrialfibrillationathighriskofbleeding
AT cappellibigazzimaurizio percutaneousleftatrialappendageocclusionanemergingoptioninpatientswithatrialfibrillationathighriskofbleeding
AT golinopaolo percutaneousleftatrialappendageocclusionanemergingoptioninpatientswithatrialfibrillationathighriskofbleeding